Cite

    Beguin, Y. et al. (2015). Safety and efficacy of azacitidine in Belgian patients with high-risk myelodysplastic syndromes, acute myeloid leukaemia, or chronic myelomonocytic leukaemia: results of a real-life, non-interventional post-marketing survey. Acta clinica belgica. 70 (1), pp. 34-43. [Online].